AstraZeneca slips on US diabetes news but Shire climbs on deal talk

Discussion in 'Market News' started by Lily, Oct 16, 2015.

  1. Lily

    Lily Forum Member

    Aug 29, 2015
    Likes Received:
    US regulators seek more data before approving AstraZeneca treatment

    AstraZeneca has slipped back in a rising market after a delay to the launch of a diabetes treatment.

    The US Food and Drug Administration declined to approve a combination of saxagliptin and dapagligiozin and said more clinical data was required. When AstraZeneca successfully defended itself against a $118bn takeover attempt by Pfizer, the company forecast the combination could produce peak revenues of £3bn.

    Continue reading...

Share This Page

free forex signals